A workable injection mold quality agreement is an operating document, not a generic promise of good quality. It should tell an overseas buyer and a global supplier what the released product baseline is, which evidence proves conformance, who may make each decision, and what happens before a known departure is shipped. Put it beside the commercial agreement, quotation, drawing package and purchase order rather than assuming any one of those documents answers every quality question.
Start with the decisions that can stop a tool build, a trial, a shipment or a specification change. The agreement should identify the controlled part and tool revisions; material route; critical, functional and cosmetic requirements; inspection and sample rules; traceability; records; change triggers; and release authority. Detail must be proportionate to the resin, geometry, tool architecture, machine, intended market and contract terms. A certificate, a first sample, or a supplier statement does not by itself approve all future cavities, lots or process conditions.
Requirement: define the buyer's written release authority and the supplier's hold-and-notify duty before production. Recommendation: use a short approval matrix so a deviation, change or shipment cannot be decided through an ambiguous email chain.
01
Set one controlled acceptance baseline before tool release
The buyer should issue a revision-controlled baseline that ranks the documents when they disagree. Typically, this includes the part drawing or 3D model with revision, agreed tolerances and datums, CTQ identification where applicable, material grade or approved material route, approved colour or appearance standard, finish or texture callouts, assembly and functional requirements, and packaging or labeling requirements. State whether a supplier DFM proposal, quotation assumption or email may change that baseline. If it may not, say so plainly and require a formal change or deviation route instead.
Ask the supplier to return a requirements review that maps each acceptance item to a proposed inspection method, gauge or test setup, sampling logic, record and responsible person. This is an evidence request, not a demand for a universal measurement system. A small cosmetic housing, a glass-filled structural component and a regulated-market part may need different controls. ISO 294-1 illustrates why molding conditions and their reporting matter when reproducibility is being considered; it does not set acceptance requirements for a buyer's production part.[2]
Approval point: before approving steel cut or a production trial, resolve every open item that could alter fit, function, appearance, resin identity, interface, safety, compliance or the tool concept. Record assumptions that remain open, their owner and their due date. Do not let an unpriced or unreviewed assumption become a de facto specification after samples are made.
02
Assign actions, evidence and authority in an approval matrix
A quality agreement should distinguish the supplier's execution duties from the buyer's product decisions. The supplier may collect evidence, contain suspect product and propose an action. The buyer's nominated engineering or quality authority should decide whether a part, revised requirement or limited concession is acceptable. FDA's quality-agreement guidance, written for drug contract manufacturing, similarly emphasizes clear allocation of activities, communication, document review and deviation handling; use its structure as a general drafting reference, not as a claim that it governs ordinary molded parts.[1]
Name primary and backup contacts, the communication channel, expected acknowledgement and escalation path. Set project-specific response times where necessary. A universal number of hours is rarely appropriate across time zones, failure severity and contractual arrangements. The matrix below is a practical starting point; the signed agreement should define the actual obligations.
| Event or decision | Supplier must provide | Buyer approval point | Release status |
|---|---|---|---|
| Production-intent trial | Tool and part revision, cavity status, material identity, relevant process record, inspection results and open issues | Approve the defined sample package or state remaining conditions | No serial-production release unless the agreed gate is met |
| Out-of-requirement part or lot | Containment, affected quantity and traceability, measured extent, risk rationale and requested disposition | Written accept, rework, reject or hold decision by named authority | Hold and segregate until disposition |
| Permanent product, tool, resin or process change | Change request, reason, affected revisions, validation or inspection impact and proposed implementation date | Approve the changed baseline before routine use | No implementation before approval unless the contract expressly provides an emergency route |
| Shipment of released product | Lot identification and agreed certificate, inspection summary or other release evidence | Use the agreed release mechanism; do not substitute an informal email for a required release | Ship only when the agreed release conditions are satisfied |
03
Request evidence that can be traced to the actual tool, resin and run
For a mold and molded part approval, request evidence that lets a later reviewer identify what was actually assessed. Depending on the programme, this can include the tool number and revision, cavity identifiers, part revision, resin manufacturer and grade or authorized material source, batch or lot where relevant, colour or additive designation, drying or conditioning information as agreed, press and auxiliary equipment identity, inspection method, sample selection, results and any secondary operation. Decide in advance which fields are mandatory for trial submissions and routine shipments.
Separate acceptance evidence from capability claims. Dimensional results may show that submitted samples met their stated limits under documented conditions, but they do not automatically establish long-term capability, mold life or a universal cycle time. If process capability, repeatability, functional testing, appearance approval, gauge correlation, material testing or traceability evidence is required, define its method, scope, acceptance threshold and approver in the agreement. The method should fit the part and the business risk rather than be copied from an unrelated programme.
Approval point: accept a submission only against the released baseline and a stated sample scope. If a condition cannot be evaluated because the gauge, datum approach, assembly counterpart, visual standard or test fixture is not ready, document that limitation and the follow-up gate. A blank signature or 'samples approved' note should not silently waive a missing requirement.
04
Control a deviation as a bounded exception, not a hidden specification revision
A deviation request is appropriate when identified product does not meet the released requirement and the supplier seeks a decision for a defined scope. It is not the same as a permanent change request. Require the request before shipment wherever practical, and require immediate notification and containment if a suspect condition has already shipped or entered assembly. The request should identify the requirement and actual departure, affected part and revision, cavity or tool context where relevant, lots and quantity, detection point, containment status, inspection extent, evidence, risk assessment, requested disposition, expiry or quantity limit, and supplier corrective action.
The buyer should assess the specific use case, not only the measured number. For a dimensional departure, ask for the datum scheme, gauge method, readings and functional or assembly implications. For a cosmetic departure, ask for location, photos under agreed viewing conditions, severity and count. For a resin, colorant or regrind issue, ask for identity and traceability, potential affected scope and the comparison to the approved route. Escalate conditions affecting safety, regulatory requirements, critical interfaces, material identity, traceability or intended performance to the appropriate engineering, quality and, where applicable, regulatory owners. A concession must not be used as a shortcut around those decisions.
Approval point: a written concession should name the exact affected revision, lots or quantity, condition, evidence reviewed, disposition, limits, expiration and approver. It should state whether the product remains segregated, how it will be marked and whether the supplier must submit corrective action. Repeated concessions for the same issue should trigger review of the tool, process, gauge, control plan or product requirement instead of becoming an informal normal condition.
05
Close the loop with change control, records and periodic review
Use change control when the team intends to alter the approved state rather than accept a one-time exception. The supplier should submit the reason, affected documents and tools, proposed effective date, inventory and work-in-process impact, risk assessment, required requalification or sample evidence, and implementation plan. The buyer should decide whether drawing, CAD, inspection plan, packing specification, approved sample, purchasing documents or validation records also need revision. No permanent requirement is changed merely because a deviation was accepted once.
Agree record ownership, format, language, retention period, access and availability when a tool moves or the supplier changes. Retain the released baseline, trial and inspection submissions, approvals, deviations, concessions, changes, corrective-action records and shipment traceability as relevant to the programme. Current U.S. device quality-system rules are sector-specific, but their focus on documented quality systems and record controls is a useful reminder that traceable records matter when the end-market requirements call for them.[3]
Review the agreement at defined programme events: supplier onboarding, DFM closure, production-intent sampling, production release, major tool maintenance, material-source changes, recurring nonconformance and transfer or end-of-life planning. This is a recommendation, not a universal audit schedule. Update the matrix only through controlled revision so procurement, engineering, supplier quality and the factory work from the same current instructions. ISO 9001 is a quality-management-system standard, but a supplier's certification or stated alignment should not replace part-specific acceptance criteria and evidence.[4]
Practical takeaway
Before you move
to the next review.
- Issue a revision-controlled acceptance baseline that identifies drawings, 3D data, CTQs, material route, appearance requirements, inspection methods, document precedence and approval owners.
- Require the supplier to map each key requirement to evidence, sample scope, traceability fields, a record and a named responsibility before tool release or production trial approval.
- Approve a written matrix for trials, changes, nonconforming lots and shipment release, including hold, notify, escalation and authority rules.
- Require each deviation request to state the affected revision, quantity or lots, cavity or tool context where relevant, measured extent, containment, risk rationale, expiration and requested disposition.
- Keep concessions temporary and traceable; use controlled change approval for any condition intended to become the new production standard.
FAQ
Common questions
What is the minimum content of an injection mold quality agreement?
At minimum, identify the controlled product and tool scope, document hierarchy, material and appearance requirements, inspection and release evidence, traceability, roles, communication, audit or access terms if agreed, deviation and change control, records, and escalation. The right depth depends on the part's risk, resin, geometry, tool architecture, target market and contract. A generic template should be completed against the actual programme rather than signed without the technical annexes.
Who should approve a molded-part deviation?
The agreement should name the buyer role with authority to approve the relevant condition, commonly a quality and engineering decision with additional product, regulatory or customer review when needed. The supplier can provide facts, containment and a proposed disposition, but should not self-authorize shipment outside the released requirement unless the contract expressly delegates that authority. Define backup approvers and escalation before a shipment is at risk.
Can an approved deviation become the new specification?
Not automatically. A deviation or concession should be limited to identified product, a stated condition and a defined quantity, lot or period. If the team wants to make the condition routine, it should use formal change control, assess the impact on the part, mold, inspection plan and downstream assemblies, revise the controlled baseline, and complete any agreed evidence or approval gates before implementation.
What evidence should a buyer request before approving an injection mold trial?
Request evidence tied to the actual trial: tool and cavity status, part revision, material identity, relevant molding conditions or approved ranges, sample selection, dimensional and applicable functional or visual results, inspection method, open issues and proposed corrective actions. Add assembly, cosmetic, material or process studies only where the released requirements call for them. Trial samples do not establish a universal mold-life, capability or cycle-time commitment.
References
Source material
- [1] U.S. FDA — Contract Manufacturing Arrangements for Drugs: Quality Agreements
- [2] ISO — ISO 294-1:2017, Plastics: Injection moulding of test specimens of thermoplastic materials
- [3] eCFR — 21 CFR Part 820, Quality Management System Regulation
- [4] ISO — ISO 9001:2026, Quality management systems — Requirements
This guide is general information for early procurement and engineering discussion. It does not replace product-specific DFM, qualification, validation, regulatory assessment or legal advice.